Artificial intelligence (AI) is already easing administrative and documentation burdens in community oncology, but panelists at the 2026 Patient-Centered Oncology Care® conference agreed that it should assist clinicians, not replace them. Moderator Rhonda Henschel, MBA, senior vice president of payer and care transformation at The US Oncology Network, asked the group to separate real value from vendor hype.
We developed a multimodal artificial intelligence (AI)-based model to generate time-dependent, individualized survival predictions for patients with childhood brain tumors. This may help better identify candidates for therapy de-escalation, maintaining survival while reducing lifelong treatment-related side effects.
Developing reliable machine learning models for healthcare can be challenging when only small datasets are available. This challenge motivates research into whether quantum computing approaches can learn useful patterns from limited symptom and risk-factor data.
Researchers in the US have developed an AI foundation model – trained on millions of facial images – that seems to be able to directly predict survival risk in patients with cancer. The team from Mass General Brigham has published a paper in The Lancet Digital Health that describes two algorithms in the model, one that estimates biological age (FAHR-FaceAge) and a second (FAHR-FaceSurvival) that generates the survival prediction forecast.
AI should not be viewed as a threat to academic oncology but as a test of its purpose. For decades, specialized knowledge was a defining feature of academic expertise and an important source of distinction, particularly at smaller academic centers, where physicians may have fewer pathways to national visibility, leadership, and recognition despite meaningful contributions to the field. As AI makes specialized knowledge increasingly accessible, preserving exclusivity should not be the goal.
Ubiquitination-regulated molecular events exert crucial regulatory effects on the initiation and progression of bladder cancer (BCa), yet clinically actionable ubiquitination-related prognostic models are still in short supply. This study is designed to construct a ubiquitination-associated prognostic signature for BCa via machine learning strategies.
When conversations turn to artificial intelligence (AI) in oncology, they usually focus on the latest algorithms, large datasets, or advances emerging from the world’s leading cancer centers. Much less attention has been given to what AI can mean for clinicians working in places where access to oncology specialists, diagnostic services, and research infrastructure is limited.
The choice of adjuvant chemotherapy in pancreatic ductal adenocarcinoma (PDAC) is mainly guided by patients' general condition. We hypothesized that tumor morphology may predict differential treatment benefit and tested whether deep learning applied to histology images could derive a biomarker of relative benefit from gemcitabine (GEM) versus modified FOLFIRINOX (mFOLFIRINOX) in resected PDAC.
What is understood regarding the risk of breast cancer is substantial, yet translating this extensive knowledge to optimally inform breast cancer screening practices has proven to be a formidable task in the pre–artificial intelligence era of medicine. Breast cancer screening guidelines issued by major medical organizations vary, with differing recommendations regarding age at screening initiation and cessation, screening interval, and modalities, creating confusion for both patients and clinicians. The common denominator of these guidelines is an emphasis on individualized, risk-based decision making; particularly with a rise in early-onset breast cancers, a one-size-fits-all approach is broadly recognized as insufficient. Yet, effective risk-stratified screening is fundamentally contingent upon accurate and reliable risk estimation, and to date, this has been tricky.
The central myth of AI is that it functions objectively. In reality, an AI model is simply a pattern-matching engine. It learns to associate certain visual features with certain diseases. But it can easily be thrown off by the background color of a person’s skin. In other words, the AI model doesn’t learn to look at the lesion itself. Instead, it picks up on the color of the surrounding skin as a clue. This means that the model’s ability to make accurate predictions essentially degrades to guesses based on skin color.
Treatment effectiveness is hindered by the phenotypic plasticity of cancer and the genetic complexity of tumors. However, CRISPR-Cas-based medicines face challenges with specificity, off-target effects, and tumor heterogeneity adaptability. This work investigates the possible combination of quantum biological processes, artificial intelligence, and nanomaterials to improve CRISPR gene editing and modulate or reverse selected malignant phenotypes. Quantum machine learning (QML) can be used to simulate quantum processes like electron tunneling in DNA repair and spin-dependent enzyme activity. To enable exact tumor phenotypic reversal, these models will be combined with optimization approaches powered by AI to direct CRISPR editing in oncogenic signaling networks. Graphene, gold nanoparticles, and lipid-based vectors are some of the nanomaterials that will be used as carriers to effectively and deliver CRISPR systems in a biocompatible manner to the cancer microenvironment. We hypothesize that selected homeostatic gene-expression states may be partially restored in experimental cancer models through the integration of quantum-informed AI, CRISPR gene alteration, and nanomaterial delivery. This integrated strategy could support future cancer therapies that move beyond tumor suppression toward controlled modulation of malignant cell states, although substantial preclinical and clinical validation remains necessary.
Pancreatic cancer remains one of the deadliest cancers today — with projections that it will become the second-leading cause of cancer death in the U.S. by 2030 since it so often goes undetected until its later stages. Artificial intelligence (AI)-powered detection methods under development at Mayo Clinic Comprehensive Cancer Center are changing that approach, helping physicians detect pancreatic cancer up to three years earlier, when it is more treatable.